18 May 2015 11:50
18 May 2015
Horizon Discovery Group plc
("Horizon", the "Company")
Result of General Meeting and Issue of Equity
On 1 May 2015, Horizon Discovery Group plc (LSE:HZD), the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, announced the conclusion of a placing to raise £25.0 million (before expenses) through the issue of 13,157,895 new ordinary shares in the Company ("New Placing Shares") at 190 pence per share (the "Placing Price"), in addition to the sale of 7,939,038 existing ordinary shares in the Company ("Existing Placing Shares") at the Placing Price, sold by certain selling shareholders (the "Placing"). The Placing was supported by both existing and new institutional investors, and included Invesco Asset Management Limited and Woodford Investment Management.
The terms of the Placing Agreement provide that the Placing is conditional upon, among other things, shareholder approval and admission of the New Placing Shares to trading on AIM becoming effective. The Company is pleased to announce that, at a general meeting of its shareholders today, the resolutions required to authorise the issue of the New Placing Shares and the disapplication of statutory pre-emption rights in relation thereto were passed. The New Placing Shares will be allotted and issued credited as fully paid and will be identical to and rank parri passu in all respects with the existing ordinary shares in the capital of the Company ("Ordinary Shares").
Accordingly, application has been made for the 13,157,895 New Placing Shares to be admitted to trading on AIM and it is expected that admission to trading on AIM ("Admission") will take place on 20 May 2015. Following Admission, the Company's enlarged issued share capital will comprise 93,472,572 Ordinary Shares with one voting right per share. No Ordinary Shares are held in Treasury. The total number of voting rights in the Company is therefore 93,472,572.
This figure of 93,472,572 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
J. P. Morgan Cazenove acted as joint bookrunner and Panmure Gordon acted as financial adviser, Nominated Adviser, broker and joint bookrunner in respect of the Placing.
ENDS
For further information from Horizon Discovery Group plc, please contact:
Consilium Strategic Communications (Financial Media and Investor Relations)
Amber Bielecka / Mary-Jane Elliott / Jessica Hodgson / Matthew Neal
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0) 7787 502 947
Email: katie.odgaard@zymecommunications.com
Panmure Gordon (UK) Limited (Financial Adviser, Nominated Adviser, Broker and Joint Bookrunner)
Corporate Finance: Freddy Crossley / Fabien Holler / Duncan Monteith
Corporate Broking: Tom Salvesen
Tel: +44 (0) 20 7886 2500
J.P. Morgan Cazenove (Joint Bookrunner)
Nicholas Hall / James Mitford
Tel: +44 (0) 20 7742 4000